Class Period: May 11, 2015 to Dec 12, 2016
Lead Plaintiff Deadline: Mar 13, 2017
Summary of Case:
A securities class action has been filed against Ophthotech Corporation ("Ophthotech" or the "Company") (NASDAQ: OPHT) on behalf behalf of all persons who purchased or otherwise acquired Ophthotech common stock between May 11, 2015, and December 12, 2016. This case has been filed in the USDC - NY (Southern).
The complaint alleges that on December 12, 2016, Ophthotech announced disappointing results for two phase 3 clinical trials designed to test the Company's experimental compound Fovista in combination with the drug Lucentis. On this news, the price of Ophthotech common stock declined from a closing share price of $38.77 per share on December 9, 2016, to a closing share price of $5.29 per share on December 12, 2016, a loss of approximately 86% on extremely heavy trading volume.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.